High frequency application of botulinum toxin therapy

A method of treating a disease or condition caused by hyperactive cholinergic innervation of a muscle in a patient, the method comprising administering a composition comprising a therapeutically effective amount of a neurotoxic component of a Clostridium botulinum toxin complex serotype A, the composition being devoid of any other protein component of the Clostridium botulinum toxin complex serotype A or subtypes to remove partially or completely the treated disease or condition symptoms, wherein

• (a) the patient is a human with a severe movement disorder or severe spasticity;
• (b) the composition is administered by local injection;
• (c) the composition is locally administered in a non-lethal dose to a muscle exhibiting hyperactive cholinergic innervation at an interval of less than eight weeks, the interval comprising a first treatment and a second treatment, wherein the amount administered in the second treatment can be lower, higher or identical to the amount administered in the first treatment;
• and
• (d) the therapeutically effective amount of a non-lethal dose of the neurotoxic component of Clostridium botulinum serotype A is locally administered to a muscle exhibiting hyperactive cholinergic innervation in a total dosage of from 500 U to 2000 U of the neurotoxic component in adults or is 15 to 20 U/kg body weight of the neurotoxic component in children.

A method for reducing facial lines or wrinkles of the skin or for removing facial asymmetries, the method comprising administering to an individual a composition comprising a therapeutically effective amount of a neurotoxic component of a Clostridium botulinum toxin complex serotype A or subtypes, the composition being devoid of any other protein component of the Clostridium botulinum toxin complex serotype A or subtypes, wherein

• (a) the individual is a human;
• (b) the therapeutically effective amount of a non-lethal dose of Clostridium botulinum serotype A is locally administered by subcutaneous or intramuscular injection into, or in vicinity of, one or more facial muscles or muscles involved in the formation of the wrinkle of the skin or the asymmetry;
• and
• (c) the composition is administered at an interval of less than eight weeks, the interval comprising a first treatment and a second treatment, wherein the amount administered in the second treatment can be lower, higher or identical to the amount administered in the first treatment;
• and
• (d) wherein the therapeutically effective non-lethal amount of Clostridium botulinum serotype A is locally administered in a total dosage from 1 U to 50 U of the neurotoxic component in adults or 15-20 Mg body weight of the neurotoxic component in children.